| Schedule of Segment Reporting Information, by Segment |
The table below is a summary of the segment loss, including significant segment expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three-Months Ended
June 30 |
|
|
Six-Months Ended
June 30 |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant Revenue |
$ |
|
227,629 |
|
$ |
|
- |
|
$ |
|
227,629 |
|
$ |
|
- |
|
Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
|
SP-3164 |
$ |
|
- |
|
$ |
|
8,406 |
|
$ |
|
15,160 |
|
$ |
|
29,443 |
|
SP-2577 |
|
|
25,767 |
|
|
|
107,977 |
|
|
|
34,077 |
|
|
|
162,472 |
|
IMP3ACT (Designable Multi-Antivirals) |
|
|
1,278,578 |
|
|
|
- |
|
|
|
2,004,921 |
|
|
|
- |
|
General and administrative: |
|
|
|
|
|
|
|
|
|
|
|
|
Professional services and Consulting |
|
|
684,042 |
|
|
|
515,414 |
|
|
|
1,586,605 |
|
|
|
1,749,109 |
|
Personnel cost |
|
|
428,922 |
|
|
|
180,933 |
|
|
|
863,980 |
|
|
|
432,041 |
|
Insurance expenses |
|
|
123,574 |
|
|
|
130,521 |
|
|
|
242,657 |
|
|
|
259,474 |
|
Facility cost and other |
|
|
90,138 |
|
|
|
22,314 |
|
|
|
167,360 |
|
|
|
51,721 |
|
Loss from operations |
|
|
2,631,021 |
|
|
|
965,565 |
|
|
|
4,914,760 |
|
|
|
2,684,260 |
|
Interest income, net |
|
|
29,592 |
|
|
|
7,740 |
|
|
|
88,703 |
|
|
|
16,902 |
|
Net loss |
$ |
|
2,373,800 |
|
$ |
|
957,825 |
|
$ |
|
4,598,428 |
|
$ |
|
2,667,358 |
|
|